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IMPACT OF BODY MASS INDEX, CALCULATED BLOOD VOLUME, SEX 
AND AGE ON OBSERVED ALPRAZOLAM CONCENTRATIONS IN URINE 
 
 
REANN ESPARZA 
 
ABSTRACT 
Benzodiazepines (BZDs) were originally developed in the 1950s to treat anxiety 
and insomnia conditions.1,2  BZDs are classified as central nervous system (CNS) 
depressants as they produce sedative and hypnotic effects by acting on the central 
nervous system’s key inhibitory neurotransmitter, gamma-aminobutyric acid type A 
receptor (GABAA).3,4  Although commonly prescribed, they are still labeled as a schedule 
IV under the Controlled Substance Act.5,6  Like all other prescribed controlled 
substances, benzodiazepines have been misused; in some cases patients do not comply 
with the recommended doses and refuse to take the drug as often as necessary while in 
others they are abused.   
The primary goal of this research was to evaluate the quantitative and qualitative 
measurements of a population taking alprazolam based on defined parameters.  The 
results were then analyzed to discuss trends and make comparisons about the effects of 
the parameters being monitored.  Qualitative results include a known prescription for the 
drug, the presence of the drug and its metabolite as well as the sex of the individual.  
Quantitative results include calculated body volume (CBV) as it paralleled to BMI, 
patient age, drug dose, drug and metabolite concentration, and specimen validity testing 
(SVT) results. 
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For the purpose of this study a data set consisting of a population prescribed 
alprazolam was provided by a therapeutic drug-testing lab. This lab utilized liquid 
chromatography tandem mass spectrometry (LC-MS/MS) to run a targeted analysis.7 The 
data analysis was conducted using R version 3.5.1 (R Foundation, Vienna, Austria).  R is 
a statistical environment for computing and graphic production.8 To transform and 
normalize the concentration of alprazolam and it’s metabolite, alpha-hydroxyalprazolam, 
in urine samples a method was adopted that accounts height, weight, sex, prescribed drug 
dose and calculated parameters for each patient including BMI, lean body weight (LBW), 
body surface area (BSA) and CBV (Equation 1 and 2). 9  Age was later accounted for by 
separating the population into predetermined age groups. 
Results revealed that the population consisted of 53.8% more females than males, 
a common trend seen in the United States.2   The number of individuals with alprazolam 
prescriptions increased as age increased. More males between the ages of 19 and 49 were 
prescribed alprazolam than women of the same age: 30.8% and 28.7%, respectively.  In 
the 70 years of age and older category, more females were prescribed alprazolam than 
males (16.2% and 13.2%, respectively).  CBV for males was higher than females and this 
trend was consistent throughout age groups.  The distribution characteristics of 
normalized alprazolam and alpha-hydroxyalprazolam most resembled that of a normal 
Gaussian distribution.  The alprazolam range for males spanned from 20 ng/mL to 
1719ng/mL while in females the range was between 20ng/mL and 1490ng/mL.  When 
age was considered, the alprazolam concentration range was larger in females ages 40-49 
vii 
and 70 years old and older. The alpha-hydroxyalprazolam concentrations were similar 
between females than males: 5-2484ng/mL and 20-2459ng/mL, respectively. This 
research illustrates that the study of individual BZDs can be used to highlight trends 
throughout a population specific to the drug of interest.  While individuals differ in many 
factors of metabolism and drug distribution, this data can be utilized as a resource for 
evaluating commonly detected/seen concentration ranges.   
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1. INTRODUCTION 
1.1 Background 
Benzodiazepines (BZDs) are commonly used in medicine for the treatment of a 
variety of medical and psychiatric conditions.  Originally developed in the 1950s, 
benzodiazepines soon surpassed the use of more harmful drugs like barbiturates to treat 
anxiety and insomnia conditions.1,2  BZDs act on the central nervous system’s key 
inhibitory neurotransmitter receptor, gamma-aminobutyric acid type A receptor 
(GABAA), to produce sedative or hypnotic effects. BZDs can act as anxiolytic or 
antianxiety agents, prevent epileptic seizures and behave as muscle relaxants.3  Due to 
these sedative/hypnotic effects, BZDs are classified as central nervous system (CNS) 
depressants.  Depending on the benzodiazepine of choice, it can be used as either a short 
term or as an extended use drug.  The condition or symptoms being treated, the dosage 
and the treatment plan are all important in determining the BZD to be prescribed.  Studies 
have shown that at low dosages BZDs act as anxiolytics and anticonvulsants, while at 
high doses sedation and hypnotic effects take precedence.4  
Although benzodiazepines are a type of prescription drug, they are still considered 
a controlled substance.  With such effects and their use in medicine many 
benzodiazepines are categorized as schedule IV drugs under the Controlled Substances 
Act (CSA).5  The CSA determines scheduling based on certain criteria: a Schedule IV is 
determined based on their use in the medical field and their lower potential for abuse than 
those drugs in lower schedules (i.e. schedules I-III).5,6  Like all other prescribed 
controlled substances, benzodiazepines have been misused; in some cases patients do not 
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comply with the recommended doses and refuse to take the drug as often as necessary 
while in others they are abused.   
 
1.2 Pharmacology of Benzodiazepines 
1.2.1 Pharmacodynamics 
The pharmacodynamics and pharmacokinetics of all benzodiazepines play an 
important role in determining how the individual will be affected by the drug as well as 
how long the drug will be in the individual’s system.  Pharmacodynamics is the way in 
which drugs act on the human body.  As mentioned previously, benzodiazepines act on 
the GABAA receptor.  Many studies have documented the identification of the five-
glycoprotein subunit, two alpha subunits, two beta subunits, and a gamma subunit, 
present within the GABA receptor; however, the alpha subunit is predominantly 
associated with BZDs.10  Once introduced into the system, the drug interacts with the 
GABAA receptor by binding and increasing the overall affinity of the receptor.  Once the 
affinity of the receptor has increased, an increase in the chloride concentration causes a 
hyperpolarization that relaxes the CNS causing the inhibitory effects of GABA.11, 12 
 
1.2.2 Pharmacokinetics 
Pharmacokinetics is how the drug moves throughout the body as it is absorbed, 
distributed, metabolized and excreted.13  The pharmacokinetic properties of 
benzodiazepines are dependent on many factors including the chemical properties, 
structure, dose, and the route of administration of the drug.11,13,14  Although 
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benzodiazepines have a standard base structure they differ in their side chains.  These 
subtle changes affect the pharmacokinetics of each benzodiazepine.  The side chains also 
determine the chemical properties of the compound including its solubility and size.  
Understanding the differences between the BZDs used is essential to knowing how the 
drug will be absorbed and distributed throughout the body.  
Benzodiazepines are administered through a variety of ways including 
intramuscularly, intravenously, orally, sublingually, and intranasal.11  The route in which 
a drug is administered plays a role in the way the drug is metabolized by determining 
how quickly it enters the system and the duration of its effects.  Once absorbed, BZDs 
undergo phase I and phase II metabolism.  In phase I metabolism, oxidation and 
reduction of the BZD transpires via enzymes, specifically cytochrome P450 (CYP450).  
In phase II metabolism, glucuronide conjugation occurs. 11,12  Benzodiazepines taken 
orally may also undergo first pass metabolism where the drug is metabolized in the 
gastrointestinal tract before entering the blood.  When absorbed, the drug is transported to 
the liver and further metabolized before it can be circulated throughout the body. 12,15 
Most, but not all, BZDs are prescribed at a dosage of less than 10mg with a 
starting dose of roughly 0.25mg.16  BZDs are classified as short acting, intermediate 
acting and long acting based on their elimination half-life, the amount of time needed to 
decrease the available amount of drug within the body.11,12  These half-lives range from 1 
- 12 hours, 12 - 40 hours and 40 - 250 hours for short, intermediate and long acting drugs, 
respectively.  However, many variables affect elimination including, but not limited to, 
genetics, organ function, pre-existing health conditions, and age.  Drug accumulation is 
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also likely to occur if an individual is ingesting the dose in intervals that overlap with the 
complete removal of drug from the body.  BZDs are broken down into their metabolites 
and excreted from the body as both parent drug and metabolite.  The amount of parent 
drug and metabolite excreted varies from drug to drug as does the ratio of parent drug to 
metabolite, however, BZDs is mainly eliminated from the body via urination.11 
 
1.3 Detection Methods and Analytic Interpretation  
1.3.1 Drug Testing 
In order to monitor drug intake and ensure adherence to the recommended daily 
dosage for those prescribed BZDs, drug testing is performed periodically.  Urine drug 
testing (UDT) is used routinely in healthcare centers, workplace and in criminal settings; 
all places in which noncompliance is monitored.3,17  UDT results are specific to each 
individual and can be useful when determining the dosage of a prescription; it can also be 
used to identify whether the prescribed drug is being abuse or if other commonly abused 
substances are present.  Although other biological samples can be used, urine is preferred.  
Not only is urine easy to collect, but it also allows for a longer detection window as 
parent drug and metabolite concentrations are higher than those in blood are present. 3,17  
 
1.3.2 Specimen Validity Testing 
To ensure the validity of the urine sample Specimen Validity Testing (SVT) must 
be completed.  Upon obtaining the biological sample the overall appearance and color are 
to be documented.3,17,18  The temperature, pH, specific gravity, creatinine levels, and 
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nitrate levels are also to be recorded as the sample may contain adulterants, a diluent or a 
urine substitute.  An adulterant is a substance added to the specimen in an attempt to 
mask or destroy content within the sample in order to prevent positive test results.  A 
diluent commonly used is water in order to dilute, or lower, the concentration of any 
compound in the sample to bring it below that of the test threshold.  A urine substitution 
is the complete replacement of human urine for another substance; this is commonly 
detected using the SVT criteria.18   
The accepted results for each SVT criteria required are as follows:  temperature 
must be documented within 4 minutes of collection and can range from 32°C - 38°C 
(roughly 90°F - 100°F); temperatures outside this range could indicate a substitution.  
The pH can range from 4.5 - 8.0 as it fluctuates throughout the day; samples with a pH 
less than 3 or greater than 11 are considered contaminated. 3,17,18  The specific gravity can 
range between 1.002 - 1.020; anything above or below that range is associated with dilute 
samples.  Creatinine concentration is greater than 20 mg/dL (milligrams per deciliter) in 
normal, unadulterated human urine; lower levels are considered diluted while 
concentrations less than 5 mg/dL are inconsistent with human urine.  Nitrite levels should 
be less than 500 ug/mL (micrograms per milliliter).  If the sample falls outside the bounds 
of these parameters it may be considered dilute or invalid and another sample will need to 
be collected. 3,17,18   
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1.3.3 Preliminary Testing 
In clinical settings as well as other places, immunoassays are used as a 
preliminary screen to determine what, if anything, the sample contains.3   There are 
several forms of immunoassays including iCup immunoassays, lateral flow 
immunoassays, enzyme-multiplied immunoassays technique (EMIT), fluorescence 
polarization immunoassays (FPIA), radioimmunoassay (RIA), and more.  The wide 
variety of immunoassays allows for quick detection of a multitude of compounds and 
their metabolites, including benzodiazepines, and can be automated. Those used in 
clinical settings such as a doctor’s office are lateral flow immunochromatography. These 
competitive immunoassays are used to give qualitative results.19, 20  In these assays 
microparticles, either colored latex or colloidal gold, are used to carry antidrug 
antibodies.  These particles are mixed with the patient’s sample and move laterally across 
what is called the test zone bringing the drug present.  If no drug is present within the 
sample, the antidrug antibodies will bind to the test zone creating a visible line.  If a drug 
is present, the antibody binds the drug and no line is visible.  A control zone is used to 
ensure the proper functioning of the assay.  The control zone will bind the antidrug 
antibodies and present a visible line.17, 19, 20  
Quantitative immunoassays are used to determine the amount of analyte present 
in the sample.  Antibodies are present on the card to interact with the drugs, if any, 
present within the individual’s urine sample.19, 20  In the immunoassay there is a set 
amount of labeled analyte (also referred to as an antigen) and an unset amount of 
unlabeled sample analyte directly received from the individual providing the urine 
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sample.  These analytes will compete against each other to bind to the binding sites of 
extremely specific anti-analyte antibody.  Once the analyte has bound to the antibody an 
antigen-antibody complex forms.  The labeled analyte can be marked with several 
distinguishing features including fluorescent and chemiluminescent moieties, functional 
groups.  These assays are considered to be quantitative by nature.  The results from UDT 
by immunoassays are quantitated through the use of calibration curves and lower limit 
cutoffs.  The lower limit cutoffs are the absolute minimum amount of analyte (drug) 
present within the sample to indicate whether an analyte of interest is present.  Analyte 
concentrations above the limit will result in a positive, while those below the limit will 
imitate a negative result. Although advantageous, immunoassays may result in false 
positives if cross reactivity with a structurally similar drug has occurred or in a false 
negative if an analyte was undetected due to a concentration below that of the assay’s 
cutoff. 3, 19, 20  Incorrect readings of the immunoassay used can also lead to misinterpreted 
results and consequences.  
 
1.3.4 Confirmatory Testing 
Qualitative and quantitative immunoassays are useful to determine the presence of 
a BZD, but they are limited and unable to determine the BZD present in the sample.  In 
order to confirm and identify the benzodiazepine present, instrumental analysis in a 
laboratory can be and is performed when necessary.  Confirmation of an immunoassay 
can be performed by either gas chromatography-mass spectrometry (GC-MS) or liquid 
chromatography-mass spectrometry (LC-MS). 12, 21  GC/MS is sensitive and accurate, 
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able to identify and quantitate even the presence of a small amount of drug.  Once a 
sample is placed on the GC it is injected into a heated port where it is vaporized. The 
mobile phase, a carrier gas, will then move the sample through the stationary phase, a 
heated column.  The sample will elute, separate, out of the column at varying retention 
times based on polarity creating a chromatogram. From the GC, the sample will enter the 
mass spectrometer. In the mass spectrometer (MS), the sample will be ionized by the ion 
source and analyzed by the mass analyzer. The detector will then produce a mass 
spectrum based on the mass to charge ratio of the components. These spectra are used to 
determine the components, fragmentation pattern, and identify the major ions of the 
sample.  These results can then be compared to reference spectra to identify the 
components and confirm the results. 3,17, 22    
Although GC is able to separate the BZDs, it requires much more time and 
consideration than immunoassays, as sample preparations and sometimes derivatization 
are needed before inserting the sample into the instrument.  It also requires knowledge on 
how to preform the testing, is time consuming and expensive.3, 12, 17   
LC-MS is similar to GC-MS; however, there are various versions of LC including 
High Performance Liquid Chromatography (HPLC) and Liquid Chromatography Tandem 
Mass Spectrometry (LC-MS/MS).  Similar to GC-MS, LC uses a mobile phase to move 
the sample through a column albeit a liquid versus a gas.  The column separates the 
components of the sample to create a chromatogram.  The sample then enters the mass 
spectrometer where it is ionized and runs through the data analyzer to the detector where 
a mass spectrum is produced.  Unlike GC, LC-MS/MS does not use reference libraries to 
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determine what was found within the sample, but instead runs a particular method with 
calibrators to quantitatively determine the presence of certain compounds within the 
sample.22  LC-MS requires as much sample preparation as GC-MS however, temperature 
does need to be factored in.  LC-MS can also detect parent and metabolite drugs without 
needing derivatization.12  Although there are myriad other types of liquid 
chromatography and mass spectrometry not mentioned, it is outside the scope of this 
research to review them all.  
To ready the urine sample for BZD analysis, sample preparation is needed. In 
order to remove the glucuronide conjugate, hydrolysis is performed.12  Hydrolysis, the 
breaking of chemical bonds, is performed in order to increase detection of an analyte.23  
This can be accomplished using enzymatic or acidic solution.  In enzymatic hydrolysis, 
an enzyme, β-glucoronidase is commonly is added directly to the sample and then 
incubated at optimal temperature and pH.  In chemical hydrolysis, an acid is added to the 
specimen.  The sample is then incubated at a certain temperature (≤100oC) for a limited 
time.  After incubation, the sample is left to cool at room temperature and the pH is 
adjusted if need be.  Immediately following, the samples are centrifuged and ready for 
extraction.23  
Solid Phase Extraction (SPE) and liquid-liquid extraction (LLE) are commonly 
used to remove the biological matrix from the sample.12  SPE uses columns with bonded 
silica sorbents that must be conditioned to have the proper chemical properties including 
pH.24  Once conditioned, the sample is run through the column to extract the sample 
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without other interferences.  LLE involves the use of an organic solvent and a pH 
adjustment to separate the analyte of interest from unwanted substances in the sample.24  
Both GC-MS and LC-MS are able to quantify a sample using calibration curves. 
These curves are created using certified reference material with known concentrations to 
produce a curve of best fit for the data.  An equation of the response (Y axis) versus 
concentration (X axis) of standards data is determined and from that the concentration of 
the sample can be calculated.22   These confirmatory techniques also allow for lower 
detection limits than immunoassays.22, 25   To ensure the proper functioning of each 
instrument, internal standards are run with each sample. These standards allow the 
analyst to monitor each individual run and assist in quantitating the amount of 
interference as well as contamination.22 
 
1.4 Benzodiazepine Abuse 
According to the National Institute on Drug Abuse (NIDA) the number of 
individuals who filled a BZD prescription rose by 67% between the years of 1996 and 
2013.26   BZD usage is seen to be twice as high in women than in men and usage 
increases with age:  in 2015, BZD use increased from 2.6% in patients 18-35 years old to 
5.4% in 36-50 year old patients to 31.4% in patients 51-64 years of age.2   As the use of 
benzodiazepines continues to grow the potential for abuse as well as inquires about 
prescription compliance will be areas of interest and concern.  Patients with symptoms 
treated by benzodiazepines are now able to acquire several prescriptions through multiple 
provider or “doctor shopping”. 27  Multiple providers writing prescriptions and doctor 
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shopping are essentially the ability of an individual to find doctors who are willing to 
give them a prescription of a BZD without much investigation into the patients 
previously prescribed medications and concurrent prescriptions.27  One way to monitor 
prescriptions is through the utilization of the prescription drug monitoring programs 
(PDMPs). 28  PDMPs store all information regarding controlled substance prescriptions in 
order for the data to be accessible to all individuals in need of such vital data including 
physicians, pharmacies, and law enforcement officers.28  
Although there are programs in place, individuals are still able to succeed in 
diverting, or illegally transferring a legally prescribed drug to another person.28  BZD 
abuse accounts for 30% of all overdose deaths second to only opioid abuse.27   According 
to the Substance Abuse and Mental Health Services Administration (SAMHSA), roughly 
a million emergency room visits involved BZDs between the year 2007 and 2011.29  
Benzodiazepine abuse was reported to have increased by 109% between 2003 and 2013 
by the Substance Abuse and Disorder treatment centers.30  In 2013, it was also reported 
that 2% of the population within the United States ages 12 and older had ingested either 
benzodiazepines or barbiturates of some type.30  An estimated 186,000 new BZD abusers 
were reported in 2010 according to the National Survey of Drug Use and Health.27 With 
an increase such as this, it is important to monitor individuals prescribed BZDs as well as 
examine prescribed usage.  These numbers express the need for in office testing and 
clinical laboratory testing if immunoassay results are incoherent or the sample presented 
appears tampered with.  A reported 22,810 deaths from prescription drug overdose by the 
Center for Disease Control and Prevention should also encourage health care providers to 
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use the systems implemented, like the PDMP, to attempt to limit pharmaceutical abuse 
and lessen the co-prescription of commonly combined drugs such as opioids and 
benzodiazepines.27 
 
1.5 Research Objective 
 Due to the increased prescription use of benzodiazepines as well as the 
increase in abuse, there is a need to monitor patients.  Accurate medical history, including 
previous history of abuse, past and current prescribed medications, and use of over-the-
counter (OTC) products are all necessary to accurately monitor a patient’s treatment. 3, 17 
Due to negative connotations associated with UDT (i.e. to catch an individual abusing 
drugs and use of the results in a court of law), patients have been found to be less likely 
to voluntarily go through drug screening and are even less likely to willingly give 
information pertaining to their history with drugs whether they have a prescription or 
not.17   
One commonly prescribed benzodiazepine is alprazolam.  Alprazolam, commonly 
known as Niravam or Xanax, was first used clinically in 1976.3  The drug is classified as 
a fast acting drug with a half-life ranging from 6-27 hours and a plasma half-life ranging 
from 12-15 hours.13  Alprazolam in particular is administered orally in pill form and is 
one BZD commonly abused because of its high potency and accessibility.3  Once taken 
alprazolam is absorbed quickly and distributed throughout the central nervous system.13  
Alprazolam is mainly protein bound with the majority bound to serum albumin.  It 
undergoes hydroxylation metabolism to produce its primary metabolite, alpha-
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hydroxyalprazolam (Figure 1).  Alprazolam is primarily excreted through urine and can 
be present for up to three days if therapeutic doses are ingested and can be detected for 
between 4-6 weeks after extended use or if abused.13, 17   
 
Figure 1. Alprazolam Metabolism and Excretion.  The metabolic pathway of alprazolam is circled in 
blue.31  
For the purpose of this study a therapeutic drug-testing lab provided a data set 
consisting of a population prescribed alprazolam. This lab utilized liquid chromatography 
tandem mass spectrometry (LC-MS/MS) to identify the parent drug and metabolite.7  
This targeted approach directed the instrumentation to look for specific ions pertaining to 
the drug of interest.7  The objective of this paper is to evaluate the quantitative and 
qualitative measurements of a population prescribed alprazolam based on defined 
parameters using urine drug test results.  The results were analyzed to discuss trends and 
make comparisons about the effects of the parameters being monitored.  Qualitative 
results included a known prescription for the drug, the presence of the drug and its 
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metabolite as well as the sex of the individual.  Quantitative results for calculated blood 
volume (CBV) as it paralleled to BMI, patient age, drug dose, drug and metabolite 
concentration and SVT were observed and accounted for.  
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2. MATERIALS AND METHODS 
2.1 Sample Preparation 
The validation of the analytical method was previously described in Enders et al. 
(2018), which utilized a LC/MSMS method which looked for a wide range of drug 
classes including amphetamines, opioids, and more in addition to benzodiazepines.7  The 
standards for alprazolam and alpha-hydroxyalprazolam were purchased from Cerilliant 
Corporation (Round Rock, TX, USA) as 1mg/mL stock solutions.  The enzyme solution 
consisted of diluting IMCSzyme® β-glucuronidase solution (IMCS, Irmo, SC) in 0.02 M 
sodium phosphate buffer, pH 7.5 to be 10,000 units/mL.  Drug-free urine was obtained 
from UTAK (Valencia, CA, USA).  Dilution samples were created using 120 µL of 
enzyme solution and 30 µL of 1,000 ng/mL nordiazepam-D5 internal standard.  Samples 
were incubated for one hour at 60°C and then solid phase extraction was performed.  The 
samples were washed with 350 µL of water, 200 µL of 100mM HCl and another 250 µL 
of water; samples were eluted with 300 µL of 80:18:2 
dichloromethane:isopropanol:ammonium hydroxide.  After reconstitution, the samples 
(30µL) were analyzed at a 10x dilution in 300 µL of 10% methanol: 90% water prior to 
analysis by LC-MS/MS.  For this method the hydrolysis control used was a morphine-3β-
D-glucuronide (Cerilliant, Round Rock, TX, USA) standard.7, 32  
 
2.2 Analytical Method 
The analysis was originally performed on an Agilent LC-MS/MS 6460 system 
using an Agilent 1290 Infinity II chromatographic system (Santa Clara, CA, USA).  The 
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analytical method was later transferred to a Thermo Ultra LC-MS/MS system (Waltham, 
MA, USA).32   Validation results were reported in the report by Enders et al.7  The 
method includes the use of water containing 5mM ammonium formate with 0.1% formic 
acid [aqueous] (Solution A) and 5mM ammonium formate in 75:25 methanol: acetonitrile 
with 0.1% formic acid (Solution B).  Cycle time was estimated to be 6.5 minutes with a 
flow rate of 0.8 ml/min.  The column used was a Phenomenex (Torrance, CA, USA) 
Kinetex 2.6 µm Phenyl- Hexyl 100Å, 50 x 4.6mm (00B-4495-EO) LC column.  An 
injection volume of 15 µL and a column temperature of 30°C was used. The analytical 
cut-off for benzodiazepines was 20ng/mL with the exception of lorazepam, which 
reached 40 ng/mL.7, 32   
 
2.3 Data Analysis 
Patient urine samples were submitted for quantitative LC/MS/MS.  The data 
analysis was conducted using R version 3.5.1 (R Foundation, Vienna, Austria).  R is a 
statistical environment for computing and graphic production.8  In order to identify a 
cohesive and representative population of patients, the test results for the benzodiazepine 
of interest was narrowed down based on the following parameters: 
1. Only patients with completed demographic information (e.g. weight, height, 
and sex) were included.  
2. Only patients prescribed and who tested positive for the selected BZD were 
included. 
3. Patients who tested positive for illicit drugs of any type were excluded. 
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4. Patient results that failed specimen validity testing (e.g. pH, specific gravity, 
and creatinine) were excluded. 
5. Patient samples lacking quantitative results of either the parent or metabolite 
drug were excluded. 
6. Patient samples with prescription dosage less than 0.25 mg and over 20 mg 
were excluded. 
7. Patient quantitative results falling outside the following ranges were 
excluded: CBV range of 2-7.5 L, and positive alprazolam and alpha-
hydroxyalprazolam concentrations of below 2000 and 2500 ng/mL 
respectively. 
The removal of certain individuals was done in an attempt to omit “extreme outliers”; 
data points outside +/- 2 SD from the mean are considered outliers on a normal Gaussian 
distribution.  
To transform and normalize the alprazolam and alpha-hydroxyalprazolam 
concentrations in the urine samples a method was adopted that accounts for more than 
one parameter associated with each patient.   The normalization process required a scale 
adjustment of included parameters to ensure commonality and consistency with all units 
to utilize the chosen equations.9  
The raw concentrations of alprazolam and alpha-hydroxyalprazolam measured in 
each urine sample were normalized and transformed as a function of height, weight, sex, 
prescribed drug dose and calculated parameters for each patient including BMI, LBW, 
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BSA and CBV as described in Equation 1 and 2.9  Age was later accounted for by 
separating the population into predetermined age groups. 
 
𝑁𝑂𝑅𝑀𝑐𝑜𝑛𝑐 =  !"(!"#$"∗!"#∗!"#!"#$ )!"#  ,        (Equation 1)  
 
𝑁𝑂𝑅𝑀𝑐𝑜𝑛𝑐 = !"(!!"#!∗!"#∗!"#!"#! )!"# ,        (Equation 2) 
 
where ln is the natural log, 𝐴𝑐𝑜𝑛𝑐 is the concentration of alprazolam (α𝑐𝑜𝑛𝑐 is the 
concentration of alpha-hydroxyalprazolam) in kg/L; LBW is the lean body weight of the 
patient in kg; BSA is the body surface area of the patient in meters squared; Dose is the 
prescribed drug dosage in kg; and CBV is the calculated blood volume in liters.  The 
normalized concentrations are then transformed into an equivalent value found within the 
standard normal distribution using Equation 39: 
 𝑍𝑠𝑐𝑜𝑟𝑒 = !"#$%&'%! !!!! .        (Equation 3) 
 
The Zscore is the standardized normal value, the 𝜇! is the mean and the 𝜎! is the standard 
deviation (SD) of the population used to construct each model (Equation 1 and 2).  The 
mean and SD for the alprazolam and alpha-hydroxyalprazolam models are dependent 
upon the population being normalized. After normalization, the mean and SD of each 
model are 0 and 1, respectively.   
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Upon retrieving the data, LBW had been calculated to account for the all content 
within the body with the exclusion of body fat.  The LBW was calculated using Equation 
49: 𝐿𝐵𝑊 𝑘𝑔 = 𝑓𝑎𝑐𝑡! ∗ 𝑤𝑒𝑖𝑔ℎ𝑡 𝑘𝑔 −  𝑓𝑎𝑐𝑡! ∗ ( !"#$!! !"!"" ∗ !!"#!! ! )!,    (Equation 4) 
 
where  𝑓𝑎𝑐𝑡! is equal to 1.1 for males and 1.07 for females, respectively, and 𝑓𝑎𝑐𝑡! is 
equal to 128 for males and 148 for females, respectively.9 
The BSA parameter is calculated for each patient as an indicator of metabolic 
mass instead of using the patient’s raw weight.  The BSA is calculated using Equation 5, 
using the Mosteller Method9: 
 
𝐵𝑆𝐴 𝑚! = (!!"#!! !" ∗!"#$!! (!")!,!"" ) .        (Equation 5) 
 
 The CBV parameter is an accumulation of the volume of blood for red blood cells 
and plasma within the patient estimated using Equation 69: 
 𝐶𝐵𝑉 𝐿 = 𝑤𝑒𝑖𝑔ℎ𝑡 𝑘𝑔 ∗ 𝐴𝑉𝐺_𝐵𝑉 (L/kg),         (Equation 6) 
 
where 𝐴𝑉𝐺_𝐵𝑉 is the estimated average blood volume of every individual patient using 
Gilcher’s Rule of Five and the weight categories found in the BMI chart classification of 
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underweight, normal, overweight, and obese (Table 1).9, 33  BMI was calculated using 
Equation 733 : 
 𝐵𝑀𝐼 !"!! = !"#$!! (!")!!"#!! (!!) .       (Equation 7) 
 
Using the calculated BMIs and BMI categories, individuals were matched to their 
Gilcher’s Rule of Five equivalent. Once the comparison has been made, the estimated 
average blood volume for each patient, male and female, was accounted for, then applied 
and used in Equation 6.  More specifically, the BMI categories of underweight, normal 
and overweight/obese paralleled those of Gilcher’s categories of thin, normal and obese, 
respectively, as is displayed in Table 1.  From there the specific average blood volume 
estimates for male and female patients were used.   
Table 1. Gilcher’s Rule of Five and Its Correspondence to the BMI Chart.  Amounts displayed are 
used in Equation 1 and 2 for patient models.9,33  
Gilcher’s Rule of Five  
(Average Blood Volume in mL/kg) 
 BMI Chart 
Males Females Classification 
Match 
BMI (kg/m2) 
65 60 Thin/underweight < 18.4 
70 65 Normal 18.5-24.9 
60 55 Overweight/Obese ≥ 25 
 
 
Normally for urine samples, creatinine and pH are used for normalization; 
however, due to the observed parameters the use of CBV was utilized instead in an 
attempt to represent the data in a Gaussian distribution.    
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 Dosage ranges were determined (Table 2) based on literature review to determine 
the most common alprazolam dosages.34   Age groups were created (Table 3) to 
subdivide the individual male and female populations. Age groups were used to monitor 
differences in the population as age increased.  
 
Table 2. Alprazolam Dose Ranges.34  
Range # Dosage (mg) 
1 0.25-3.9 
2 4-6.9 
3 7-9.9 
4 ≥ 10 
 
Table 3. Age Groups for Male and Female Subpopulations.  
Age Groups (years of age) 
<18 
19-29 
30-39 
40-49 
50-59 
60-69 
≥ 70 
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3. RESULTS  
3.1 Study Population (includes both females and males) 
 Through the filtering process the original population of 16,627 alprazolam patient 
data points (both female and male) was reduced to 6,388.  The resulting population, of 
which 4,372 were female (68.4% of the entire population) and 2,016 were men (31.5% of 
the entire population), had an overall age range of 17 to 99 years of age with an average 
age of 56.69 years of age.  The daily dosages ranged from 0.25mg to 20mg a day with an 
average of 2.29mg and a median of 2mg; the median indicates the most commonly 
prescribed dose fell within the range number 1 (0.25-3.9mg/per day) seen in Table 2.  
The CBV of the population ranged from 2.25L - 7.52L with an average of 4.84L and a 
median of 4.72L (Figure 2). 
 The observed raw concentrations seen in the population are shown in Figure 3.  
These data were used to create the normalized and transformed alprazolam concentration 
model shown in Figure 4.  The data mostly resembles that of a normal Gaussian peak 
where 68% of the population is between +/- 1 standard deviation, 95% of the population 
is between +/- 2 standard deviation and 99.7% is between +/- 3 standard deviations. 
There is, however, slight deviation from a normal curve in the normalized data for 
alprazolam as a marginal amount of skewing to the right was observed while the raw 
concentrations observed were more evidently skewed to the right demonstrating that the 
distribution is asymmetrical (Figures 3 and 4).  This type of skewing indicates that the 
raw mean of the population’s alprazolam concentration (185.80ng/mL) was greater than 
that of the median (110ng/mL).  The normalized mean (0ng/mL) was also greater than 
23 
the median (-0.06ng/mL).  The raw alprazolam concentrations ranged from 20ng/mL-
1719ng/mL.  The same trend was observed in the raw and normalized alpha-
hydroxyalprazolam concentrations.  The raw mean and median of the population’s alpha-
hydroxyalprazolam concentration are 351.93ng/mL and 199ng/mL, respectively while the 
normalized mean and median are 0ng/mL and -0.07ng/mL, respectively (Figures 5 and 
6).  The raw alpha-hydroxyalprazolam concentrations ranged form 5ng/mL to 
2484ng/mL.  
 
Figure 2. Histogram of the CBV for the Population. The average CBV was 4.84L with a SD of 1.04L. 
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Figure 3. Histogram of Raw Alprazolam Concentrations Found in the Population. Concentrations 
range from 20 to 1719ng/mL with an average of 185.80ng/mL and a median of 110ng/mL. 
 
 
 
Figure 4. Histogram of Normalized Alprazolam Concentrations Found in the Population.  The x-axis 
is labeled as that of a normal distribution with SD being the unit of measurement. Average and SD of the 
normalized data are 0 and 1, respectively (median= -0.06ng/mL).  
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Figure 5. Histogram of Raw Alpha-hydroxyalprazolam Concentrations Found in the Population. 
Concentrations range from 5 to 2484ng/mL with an average of 351.93ng/mL and a median of 199ng/mL. 
 
 
Figure 6. Histogram of Normalized Alpha-hydroxyalprazolam Concentrations Found in the 
Population.  The x-axis is labeled as that of a normal distribution with SD being the unit of measurement. 
Average and SD of the normalized data are 0 and 1, respectively (median= -0.07ng/mL).  
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3.2 Female Population 
3.2.1 Overall Female Population 
 The population age range was from 17.84 to 99.74 years of age with an average 
and median of 57.14 and 57.69 years of age, respectively.  In this population less than 1% 
(roughly 0.02%) fell within the 18 years of age and under category, 2.0% fell within the 
age range of 19 - 29 years of age, 9.5% fell within 30-39 years of age, 17.2% fell within 
40-49 years of age, 28.4% fell within 50-59 years of age, 26.4% fell within 60-69 years 
of age, and 16.2% fell in the 70 years of age or older range. The CBV (Figure 6) of the 
female population ranged from 2.23L - 7.33L (average= 4.50L; median=4.34L).  The 
daily doses ranged from 0.25 to 20mg with a mean of 2.30mg and a median of 2mg 
suggesting the most common dose range for females was between 0.25mg - 3.9mg per 
day.  
 Similar to the overall population, the raw concentrations of the female population 
used to create the normalized data displayed skewing while the normalized data 
resembled that of a normal bell curve (Figure 8 and 9).  The normalized data for 
alprazolam concentrations found in the urine samples were slightly deviated to the right 
while the raw concentrations observed were notably skewed to the right demonstrating an 
asymmetrical distribution.  The raw alprazolam concentrations range from 20ng/mL to 
1490ng/mL with a mean of 179.25ng/mL and a median of 106ng/mL; the mean was 
greater than the median, a commonality in positive, or right skewing.  The normalized 
data had a mean of 0ng/mL and a median of -0.07ng/mL.  The raw and normalized alpha-
hydroxyalprazolam concentrations displayed those same distributions (Figure 10 and 11).  
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The range of the raw data was between 5 and 2484ng/mL with a mean and median of 
347.87ng/mL and 196ng/mL, respectively.  The normalized mean and median were 
0ng/mL and -0.06ng/mL, respectively.   
 
Figure 7. Histogram of the CBV for the Female Population. The average CBV was 4.50L with a SD of 
0.94L. 
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Figure 8. Histogram of Raw Alprazolam Concentrations Found in the Female Population. 
Concentrations range from 20 to 1490ng/mL with an average of 179.25ng/mL and a median of 106ng/mL. 
 
 
Figure 9. Histogram of Normalized Alprazolam Concentrations Found in the Female Population.  
The x-axis is labeled as that of a normal distribution with SD being the unit of measurement. Average and 
SD of the normalized data are 0 and 1, respectively (median= -0/07ng/mL).  
 
29 
 
Figure 10. Histogram of Raw Alpha-hydroxyalprazolam Concentrations Found in the Female 
Population. Concentrations range from 5 to 2484ng/mL with an average of 347.87ng/mL and a median of 
196ng/mL. 
 
 
Figure 11. Histogram of Normalized Alpha-hydroxyalprazolam Concentrations Found in the Female 
Population.  The x-axis is labeled as that of a normal distribution with SD being the unit of measurement. 
Average and SD of the normalized data are 0 and 1, respectively (median= -0.06ng/mL). 
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3.2.2 Female Population under the age of 18 
 Insufficient data (n=1). No results to report.  
 
3.2.3 Female Population between 19-29 years of age 
 The females in this population had a CBV range of 2.64L - 7.14L with an average 
of 4.47L and a median of 4.22L.  The doses within this subpopulation ranged between 
0.25mg and 8mg.  The median dosage was 1.5ng/mL and the average was 2.15ng/mL.  
The raw concentrations of alprazolam ranged from 22ng/mL - 883ng/mL with an average 
of 178.13ng/mL and a median of 95.5ng/mL (Figure 12).  The normalized data was 
slightly skewed to the right with an average of 0 ng/mL and a median of -0.04ng/mL 
(Figure 12).  The raw alpha-hydroxyalprazolam concentrations range from 8ng/mL – 
1536ng/mL with an average of 377.56 ng/mL and a median of 235 ng/mL (Figure 13).  
The normalized alpha-hydroxyalprazolam data displayed a symmetrical distribution with 
an average of 0ng/mL and a median of 0.0ng/mL (Figure 13). 
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Figure 12. Histograms of Raw (left) and Normalized (right) Alprazolam Concentrations Found in 
Females Ages 19-29.  
 
 
Figure 13. Histograms of Raw (left) and Normalized (right) Alpha-hydroxyalprazolam 
Concentrations Found in Females Ages 19-29. 
 
3.2.4 Female Population between 30-39 years of age 
The females in this population had a CBV range of 2.64L - 7.14L with an average 
of 4.47L and a median of 4.22L.  The doses within this subpopulation ranged between 
0.25mg and 15mg.  The median dosage was 2ng/mL and the average was 2.37ng/mL.  
The raw concentrations of alprazolam ranged from 20ng/mL to 1442ng/mL with an 
average of 170.57ng/mL and a median of 110ng/mL (Figure 14).  The normalized data 
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was slightly skewed to the right with an average of 0 ng/mL and a median of -0.01ng/mL 
(Figure 14).  The raw alpha-hydroxyalprazolam concentrations range from 13ng/mL to 
2382ng/mL with an average of 389.24ng/mL and a median of 231.5ng/mL (Figure 15).  
The normalized alpha-hydroxyalprazolam data was slightly skewed to the right with an 
average of 0ng/mL and a median of -0.11ng/mL (Figure 15).  
 
 
Figure 14. Histograms of Raw (left) and Normalized (right) Alprazolam Concentrations Found in 
Females Ages 30-39. 
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Figure 15. Histograms of Raw (left) and Normalized (right) Alpha-hydroxyalprazolam 
Concentrations Found in Females Ages 30-39. 
 
3.2.5 Female Population between 40-49 years of age 
The females in this population had a CBV range of 2.59L to 7.33L with an 
average of 4.80L and a median of 4.59L.  The doses within this subpopulation ranged 
between 0.25mg - 20mg.  The median dosage was 2ng/mL and the average was 
2.33ng/mL.  The raw concentrations of alprazolam ranged from 20ng/mL - 1405ng/mL 
with an average of 179.99ng/mL and a median of 101.5ng/mL (Figure 16).  The 
normalized data was slightly skewed to the right with an average of 0ng/mL and a 
median of -0.04ng/mL (Figure 16).  The raw alpha-hydroxyalprazolam concentrations 
ranged from 13ng/mL - 2480ng/mL with an average of 359.78ng/mL and a median of 
197ng/mL (Figure 17).  The normalized alpha-hydroxyalprazolam data was slightly 
skewed to the right with an average of 0ng/mL and a median of -0.02ng/mL (Figure 17). 
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Figure 16. Histograms of Raw (left) and Normalized (right) Alprazolam Concentrations Found in 
Females Ages 40-49. 
 
 
 
Figure 17. Histograms of Raw (left) and Normalized (right) Alpha-hydroxyalprazolam 
Concentrations Found in Females Ages 40-49. 
 
3.2.6 Female Population between 50-59 years of age 
The females in this population had a CBV range of 2.26L to 7.28L with an 
average of 4.53L and a median of 4.37L.  The doses within this subpopulation ranged 
between 0.25mg and 20mg.  The median dosage was 2ng/mL and the average was 
2.28ng/mL.  The raw concentrations of alprazolam range from 20ng/mL - 1490ng/mL 
with an average of 193.17ng/mL and a median of 108ng/mL (Figure 18).  The normalized 
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data was slightly skewed to the right with an average of 0 ng/mL and a median of -0.10 
ng/mL (Figure 18).  The raw alpha-hydroxyalprazolam concentrations ranged from 
10ng/mL - 2484ng/mL with an average of 372.95ng/mL and a median of 214ng/mL 
(Figure 19).  The normalized alpha-hydroxyalprazolam data was slightly skewed to the 
right with an average of 0ng/mL and a median of -0.07ng/mL (Figure 19). 
 
Figure 18. Histograms of Raw (left) and Normalized (right) Alprazolam Concentrations Found in 
Females Ages 50-59. 
 
 
Figure 19. Histograms of Raw (left) and Normalized (right) Alpha-hydroxyalprazolam 
Concentrations Found in Females Ages 50-59. 
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3.2.7 Female Population between 60-69 years of age 
The females in this population had a CBV range of 2.37L to 7.31L with an 
average of 4.45L and a median of 4.32L.  The doses within this subpopulation ranged 
between 0.25mg and 20mg.  The median dosage was 2ng/mL and the average was 
2.22ng/mL.  The raw concentrations of alprazolam range from 20ng/mL - 1461ng/mL 
with an average of 180.61ng/mL and a median of 108ng/mL (Figure 20).  The normalized 
data was slightly skewed to the right with an average of 0 ng/mL and a median of -0.10 
ng/mL (Figure 20).  The raw alpha-hydroxyalprazolam concentrations ranged from 
5ng/mL - 2344ng/mL with an average of 337.45ng/mL and a median of 197ng/mL 
(Figure 21).  The normalized alpha-hydroxyalprazolam data was slightly skewed to the 
right with an average of 0ng/mL and a median of -0.06ng/mL (Figure 21). 
 
 
Figure 20. Histograms of Raw (left) and Normalized (right) Alprazolam Concentrations Found in 
Females Ages 60-69. 
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Figure 21. Histograms of Raw (left) and Normalized (right) Alpha-hydroxyalprazolam 
Concentrations Found in Females Ages 60-69. 
 
 
3.2.8 Female Population ages 70 and older 
The females in this population had a CBV range of 2.31L - 7.18L with an average 
of 4.19L and a median of 4.10L.  The doses within this subpopulation ranged between 
0.25mg and 16mg.  The median dosage was 2ng/mL and the average was 2.40ng/mL.  
The raw concentrations of alprazolam range from 20ng/mL - 1449ng/mL with an average 
of 157.32ng/mL and a median of 95ng/mL (Figure 22).  The normalized data was slightly 
skewed to the right with an average of 0 ng/mL and a median of -0.02 ng/mL (Figure 22).  
The raw alpha-hydroxyalprazolam concentrations ranged from 12ng/mL - 2268ng/mL 
with an average of 280.12ng/mL and a median of 155ng/mL (Figure 23).  The normalized 
alpha-hydroxyalprazolam data was slightly skewed to the right with an average of 
0ng/mL and a median of -0.04ng/mL (Figure 23). 
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Figure 22. Histograms of Raw (left) and Normalized (right) Alprazolam Concentrations Found in 
Females 70 and Older. 
 
 
Figure 23. Histograms of Raw (left) and Normalized (right) Alpha-hydroxyalprazolam 
Concentrations Found in Females Ages 70 and Older. 
 
3.3 Male Populations 
3.3.1 Overall Male Population 
For this population ages ranged from 22.39 years of age to 92.94 years of age 
with an average age of 55.75 years of age and a median of 57.15 years of age.  In this 
population 4.2% fell within the age range of 19-29 years of age, 11.6% fell within 30-39 
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years of age, 14.8% fell within 40-49 years of age, 28.7% fell within 50-59 years of age, 
27.1% fell within 60-69 years of age, and 13.2% fell in the 70 years of age or older range.  
The CBV (Figure 24) of the overall male population ranged from 3.07L - 7.53L. The 
average calculated blood volume was 5.57L and the median was 5.50L. The daily doses 
ranged from 0.25mg - 20mg with a mean of 2.27mg and a median of 2mg suggesting the 
most common dose range for males was in range 1; it was between 0.25mg - 3.9mg per 
day.    
The raw concentrations of the male population used to create the normalized 
alprazolam data displayed skewing, while the normalize data resembled that of a normal 
bell curve (Figure 25 and 26).  The normalized data for alprazolam concentrations found 
in the urine samples were slightly deviated to the right while the raw concentrations 
observed were notably skewed to the right demonstrating an asymmetrical distribution.  
The raw alprazolam concentrations ranged from 20ng/mL - 1719ng/mL with a mean of 
200.29ng/mL and a median of 119ng/mL; the mean was greater than the median, a 
commonality in positive, or right skewing.  The normalized data had a mean of 0ng/mL 
and a median of -0.03ng/mL.  The range of the raw alpha-hydroxyalprazolam data 
(Figure 27) was between 20ng/mL and 2459ng/mL with a mean and median of 
361.10ng/mL and 204ng/mL, respectively.  The normalized mean and median were 
0ng/mL and -0.06, respectively (Figure 28).   
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Figure 24. Histogram of the CBV for the Male Population. The average CBV was 5.57L with a SD of 
0.85L. 
 
 
 
Figure 25. Histogram of Raw Alprazolam Concentrations Found in the Male Population. 
Concentrations range from 20 to 1719ng/mL with an average of 200.29ng/mL and a median of 119ng/mL. 
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Figure 26. Histogram of Normalized Alprazolam Concentrations Found in the Male Population.  The 
x-axis is labeled as that of a normal distribution with SD being the unit of measurement. Average and SD 
of the normalized data are 0 and 1, respectively (median= -0.03ng/mL).  
 
 
Figure 27. Histogram of Raw Alpha-hydroxyalprazolam Concentrations Found in the Male 
Population. Concentrations range from 20 to 2459ng/mL with an average of 361.10ng/mL and a median of 
204ng/mL. 
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Figure 28. Histogram of Normalized Alpha-hydroxyalprazolam Concentrations Found in the Male 
Population.  The x-axis is labeled as that of a normal distribution with SD being the unit of measurement. 
Average and SD of the normalized data are 0 and 1, respectively (median= -0.06ng/mL). 
 
3.3.2 Male Population under the age of 18 
 Insufficient data (n=9). No results to report. 
 
3.3.3 Male Population between 19-29 years of age 
 The males in this population had a CBV range of 3.57L - 7.43 with an average of 
5.24L and a median of 5.08L.  The doses within this subpopulation ranged between 
0.25mg and 5mg.  The median dosage was 2ng/mL and the average was 2.09ng/mL.  The 
raw concentrations of alprazolam ranged from 22ng/mL - 883ng/mL with an average of 
168.79ng/mL and a median of 108 ng/mL (Figure 29).  The normalized data was slightly 
skewed to the left with an average of 0ng/mL and a median of 0.01ng/mL (Figure 29).  
The raw alpha-hydroxyalprazolam concentrations ranged from 31ng/mL – 1519ng/mL 
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with an average of 383.09 ng/mL and a median of 243 ng/mL (Figure 30).  The 
normalized alpha-hydroxyalprazolam data was slightly skewed to the right with an 
average of 0ng/mL and a median of -0.19ng/mL (Figure 30). 
 
Figure 29. Histograms of Raw (left) and Normalized (right) Alprazolam Concentrations Found in 
Males Ages 19-29.  
 
 
Figure 30. Histograms of Raw (left) and Normalized (right) Alpha-hydroxyalprazolam 
Concentrations Found in Males Ages 19-29. 
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3.3.4 Male Population between 30-39 years of age 
 The males in this population had a CBV range of 3.39L - 7.53L with an average 
of 5.68L and a median of 5.60L.  The doses within this subpopulation ranged between 
0.25mg and 20mg.  The median dosage was 2ng/mL and the average was 2.46ng/mL.  
The raw concentrations of alprazolam ranged from 20ng/mL - 1608ng/mL with an 
average of 234.30ng/mL and a median of 132ng/mL (Figure 31).  The normalized data 
was slightly skewed to the right with an average of 0 ng/mL and a median of -0.05 ng/mL 
(Figure 31).  The raw alpha-hydroxyalprazolam concentrations ranged from 24ng/mL -
2459ng/mL with an average of 506.78ng/mL and a median of 289ng/mL (Figure 32).  
The normalized alpha-hydroxyalprazolam data was slightly skewed to the right with an 
average of 0ng/mL and a median of -0.01ng/mL (Figure 32). 
 
Figure 31. Histograms of Raw (left) and Normalized (right) Alprazolam Concentrations Found in 
Males Ages 39-39.    
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Figure 32. Histograms of Raw (left) and Normalized (right) Alpha-hydroxyalprazolam 
Concentrations Found in Males Ages 30-39. 
 
3.3.5 Male Population between 40-49 years of age 
 
The males in this population had a CBV range of 4.06L - 7.48L with an average 
of 5.81L and a median of 5.81L.  The doses within this subpopulation ranged between 
0.25mg and 12mg.  The median dosage was 1.5ng/mL and the average was 2.09ng/mL.  
The raw concentrations of alprazolam ranged from 20ng/mL to 1198ng/mL with an 
average of 201.22ng/mL and a median of 115.5ng/mL (Figure 33).  The normalized data 
was slightly skewed to the right with an average of 0 ng/mL and a median of -0.07 ng/mL 
(Figure 33).  The raw alpha-hydroxyalprazolam concentrations ranged from 22ng/mL to 
2295ng/mL with an average of 395.10ng/mL and a median of 229ng/mL (Figure 34).  
The normalized alpha-hydroxyalprazolam data was skewed to the left with an average of 
0ng/mL and a median of -0.11ng/mL (Figure 34). 
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Figure 33. Histograms of Raw (left) and Normalized (right) Alprazolam Concentrations Found in 
Males Ages 40-49. 
 
Figure 34. Histograms of Raw (left) and Normalized (right) Alpha-hydroxyalprazolam 
Concentrations Found in Males Ages 40-49. 
 
3.3.6 Male Population between 50-59 years of age 
The males in this population had a CBV range of 3.24L to 7.48L with an average 
of 5.62L and a median of 5.50L.  The doses within this subpopulation ranged between 
0.25mg and 15mg.  The median dosage was 1.5ng/mL and the average was 2.14ng/mL.  
The raw concentrations of alprazolam range from 20ng/mL - 1586ng/mL with an average 
of 207.77ng/mL and a median of 132ng/mL (Figure 35).  The normalized data was 
slightly skewed to the right with an average of 0 ng/mL and a median of -0.02 ng/mL 
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(Figure 35).  The raw alpha-hydroxyalprazolam concentrations ranged from 22ng/mL - 
2385ng/mL with an average of 351.27ng/mL and a median of 199ng/mL (Figure 36).  
The normalized alpha-hydroxyalprazolam data was slightly skewed to the right with an 
average of 0ng/mL and a median of -0.08ng/mL (Figure 36). 
 
 
Figure 35. Histograms of Raw (left) and Normalized (right) Alprazolam Concentrations Found in 
Males Ages 50-59. 
 
 
 
Figure 36. Histograms of Raw (left) and Normalized (right) Alpha-hydroxyalprazolam 
Concentrations Found in Males Ages 50-59. 
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3.3.7 Male Population between 60-69 years of age 
The males in this population had a CBV range of 3.15L - 7.48L with an average 
of 5.55L and a median of 5.50L.  The doses within this subpopulation ranged between 
0.25mg and 20mg.  The median dosage was 2ng/mL and the average was 2.41ng/mL.  
The raw concentrations of alprazolam ranged from 20ng/mL - 1719ng/mL with an 
average of 194.45ng/mL and a median of 116ng/mL (Figure 37).  The normalized data 
was slightly skewed to the right with an average of 0 ng/mL and a median of -0.01 ng/mL 
(Figure 37).  The raw alpha-hydroxyalprazolam concentrations ranged from 20ng/mL - 
2400ng/mL with an average of 305.35ng/mL and a median of 184ng/mL (Figure 38).  
The normalized alpha-hydroxyalprazolam data was slightly skewed to the right with an 
average of 0ng/mL and a median of -0.03ng/mL (Figure 38). 
 
 
Figure 37. Histograms of Raw (left) and Normalized (right) Alprazolam Concentrations Found in 
Males Ages 60-69.  
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Figure 38. Histograms of Raw (left) and Normalized (right) Alpha-hydroxyalprazolam 
Concentrations Found in Males Ages 60-69. 
 
3.3.8 Male Population with 70 years of age and older 
The males in this population had a CBV range of 3.07L - 7.51L with an average 
of 5.26L and a median of 5.21L.  The doses within this subpopulation ranged between 
0.25mg and 16mg.  The median dosage was 2ng/mL and the average was 2.34ng/mL.  
The raw concentrations of alprazolam ranged from 20ng/mL to 1162ng/mL with an 
average of 175.35ng/mL and a median of 111.5ng/mL (Figure 39).  The normalized data 
was slightly skewed to the right with an average of 0 ng/mL and a median of -0.09 ng/mL 
(Figure 39).  The raw alpha-hydroxyalprazolam concentrations ranged from 22ng/mL - 
2198ng/mL with an average of 323.46ng/mL and a median of 205.5ng/mL (Figure 40).  
The normalized alpha-hydroxyalprazolam data was slightly skewed to the right with an 
average of 0ng/mL and a median of -0.16ng/mL (Figure 40). 
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Figure 39. Histograms of Raw (left) and Normalized (right) Alprazolam Concentrations Found in 
Males 70 and Older.  
 
 
Figure 40. Histograms of Raw (left) and Normalized (right) Alpha-hydroxyalprazolam 
Concentrations Found in Males 70 and Older. 
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4. DISCUSSION 
 The use of benzodiazepines is frequently seen in both males and females.  Despite 
programs in place to monitor prescription usage, cases of abuse with these drugs are 
growing, as is the sheer number of individuals with access to prescriptions.  Prescription 
adherence is of the upmost importance to ensure abuse does not occur.  More specifically, 
alprazolam use is increasing due to not only symptoms and doctor diagnosis, but through 
doctor shopping and abuse. With this in mind, urine drug testing in clinical facilities is 
mandated.4, 28, 29  
 
4.1 Population Size  
The number of patients with an alprazolam prescriptions differed between males 
and females.  The female population had 2,356 more individuals than the male 
population, meaning they had 53.8% more participants.  These figures align with the 
overall trends of BZD usage in the United States.2   
 
4.2 Age Ranges 
 The original population consisted of participants in the 18 years of age and 
younger subpopulation; however, due to the filtering process most of these individuals 
were removed.  An overall increase in the number of individuals with alprazolam 
prescriptions was seen as age increased.  The findings of this paper show that a higher 
percentage of individuals in the male population started taking alprazolam at a younger 
age  (between 19-49 years old) than those in the female population: 30.8% and 28.7%, 
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respectively.  It also shows that a higher percentage of females were still taking 
alprazolam in the 70 years of age and older category than that of males:  16.2% and 
13.2%, respectively.   
 
4.3 Calculated Blood Volume (CBV) 
The calculated blood volume for males was higher than that seen in the overall 
female population.  This was consistent with the higher estimated blood volume numbers 
seen in Gilcher’s Rule (Table 1). The ranges are consistent throughout the different age 
groups.  
 
4.4 Drug Dose 
 The most commonly prescribed drug dose for the entire population was 2mg for 
both males and females; the most common drug dose range was from 0.25mg to 3.9mg.  
This did not change once males and females were separated; age divisions did not affect 
this either.  These results showed that most individuals require less than 10mg to treat 
their symptoms.  No statistical comparison (i.e. t-tests) of doses between male and 
females was incorporated into this study due to the inclusion of dose in the normalization 
equation.  
 
4.5 Drug and Metabolite Concentration 
 Although the raw distributions seen were all skewed they were consistently 
skewed between each subpopulation and division made.  Distributions most resembling 
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normal Gaussian distributions were observed for the normalized data of each 
subpopulation and division.  The concentration range, as well as the average and median 
concentrations, of alprazolam was larger in males (20-1719ng/mL) than in females (20-
1490ng/mL); however, when age was considered, the alprazolam concentration range 
was larger in females ages 40-49 and 70 years old and older than in males.  Unlike the 
trend seen with the parent drug, the metabolite, alpha-hydroxyalprazolam, was seen in 
higher concentrations for females.  The concentration range for alpha-hydroxyalprazolam 
in females was 5ng/mL - 2484ng/mL and in males it was 20ng/mL - 2459ng/mL.  The 
reason for differences in the ranges seen in the female and male metabolite 
concentrations is unknown; however, it may have to do with the rate of their metabolism. 
For both males and females, higher concentration were found in older individuals than in 
younger ones as was expected based on previous studies.2   
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5. CONCLUSIONS 
 The term “benzodiazepines” is a commonly used to describe an entire group of 
drugs with similar effects, however; some individual analytes within this group are taken 
more commonly than others.  This research illustrates that the study of individual BZDs 
can be used to highlight trends seen throughout a population.  The data presented in this 
study displays the commonalities and differences seen between the females and males 
within a population prescribed alprazolam as well as the trends seen in the entire study 
population.  Using these data, providers could monitor acceptable drug concentrations or 
at least have an understanding of where patient urine drug test results should fall.  
Although this study does not factor in individual metabolic rate or previous health issues, 
it demonstrates the possibilities that are given when certain drugs within a class are 
studied individually.  
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